Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre.
In a medical centre in northern Taiwan, 60 patients had bloodstream infection caused by Enterobacter cloacae from 1 January 2002 to 30 April 2003. Forty (66.7%) were nosocomial and 26 were caused by multiresistant isolates. Twenty patients died due to the infection. Central venous catheterization and mechanical ventilation were relative risks for nosocomial E. cloacae infection. Age and mechanical ventilation were risk factors for multiresistant E. cloacae infection. Mortality was associated with multiresistant isolates and polymicrobial infection. Pulsed-field gel electrophoresis (PFGE) analysis showed, the 26 multiresistant isolates comprised 12 different types, with type A predominating (12 isolates). Excluding the patients infected with PFGE type A, central venous catheterization was a relative risk for infection, and polymicrobial infection was a risk factor for mortality. All but one of the 26 multiresistant isolates had the extended-spectrum beta-lactamase SHV-12. TEM-1 and ampC beta-lactamase genes were also detected in 25 of the 26 multiresistant isolates. Southern blotting indicated that the SHV-12 gene was located on plasmids. Eleven of the 26 multiresistant isolates had minimum inhibitory concentrations (MIC) > or =16 mg/L for cefepime, which was reduced by the addition of sulbactam for most isolates, resulting in susceptibility. The combination of cefepime and sulbactam may be effective in the treatment of multiresistant E. cloacae bloodstream infection.
Liu
C-P
CP
Division of Infectious Diseases, Department of Medicine, Mackay Memorial Hospital, Taipei, Taiwan, ROC.
Wang
N-Y
NY
Lee
C-M
CM
Weng
L-C
LC
Tseng
H-K
HK
Liu
C-W
CW
Chiang
C-S
CS
Huang
F-Y
FY
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000201:enzymology* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D003428:Cross Infection / Q000201:enzymology* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D018432:Drug Resistance, Multiple; D016972:Enterobacter cloacae / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000201:enzymology* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D012121:Respiration, Artificial / Q000009:adverse effects; D012307:Risk Factors; D018805:Sepsis / Q000201:enzymology* / Q000453:epidemiology / Q000517:prevention & control; D013624:Taiwan / Q000453:epidemiology; D001618:beta-Lactamases / Q000302:isolation & purification
C107198:beta-lactamase SHV-12; D001618:beta-Lactamases